98063-21-9

Basic information

• Product Name: (r)-Aminocarnitine
• Synonyms: emeriamine;(2R)-2-Amino-3-carboxy-N,N,N-trimethyl-1-propanaminium Inner Salt;(R)-3-Amino-4-(trimethylammonio)butyrate;(R)-2-Amino-3-carboxylato-N,N,N-trimethyl-1-propanaminium;(R)-3-Amino-4-trimethylaminiobutyrate;(R)-3-Carboxylato-2-amino-N,N,N-trimethyl-1-propanaminium;Ameriamine;(R)-Aminocarnitine
• CAS NO: 98063-21-9
• Molecular Formula: C₇H₁₆N₂O₂
• Molecular Weight: 160.21
• Product Categories: Chemical Amines;Amines;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 98063-21-9.mol
• Article Data: 10

Chemical Properties

• Melting Point: 150°C
• Appearance: /
• Storage Temp.: Hygroscopic, -20?C Freezer, Under Inert Atmosphere
• Solubility: Methanol (Slightly), Water (Slightly)
• Stability: Hygroscopic
• CAS DataBase Reference: (r)-Aminocarnitine(CAS DataBase Reference)
• NIST Chemistry Reference: (r)-Aminocarnitine(98063-21-9)
• EPA Substance Registry System: (r)-Aminocarnitine(98063-21-9)

Safety Data

• Hazardous Substances Data: 98063-21-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C7H16N2O2/c1-9(2,3)5-6(8)4-7(10)11/h6H,4-5,8H2,1-3H3/t6-/m1/s1

Upstream product

• 108-95-2 phenol 
• 108919-55-7 (R)-3-(tosylamino)-4-(trimethylammonio)butanoate 

Downstream Products

• 1059702-81-6 (R)-3-(3-(4-(benzyloxy)phenyl)ureido)-4-(trimethylammonio)butanoate acetate 
• 1059702-77-0 (R)-3-(3-(4-phenoxyphenyl)ureido)-4-(trimethylammonio)butanoate 
• 1059702-75-8 (R)-3-(3-(2-chloro-4-(trifluoromethyl)phenyl)ureido)-4-(trimethylammonio)butanoate 
• 1059702-79-2 (R)-3-(3-(4-(thiophen-2-yl)phenyl)ureido)-4-(trimethylammonio)butanoate 
• 1059702-70-3 (R)-3-(4-propoxybenzamido)-4-(trimethylammonio)butanoate 
• 1059702-71-4 (R)-3-(4-(thiophene-2-sulfonamido)benzamido)-4-(trimethylammonio)butanoate 
• 1059702-72-5 (R)-3-(5-(phenylethynyl)furan-2-carboxamido)-4-(trimethylammonio)butanoate 
• 1059702-76-9 (R)-3-(3-(4-octylphenyl)ureido)-4-(trimethylammonio)butanoate 
• 1059702-78-1 (R)-3-(3-(4-methyl-2-phenylthiazol-5-yl)ureido)-4-(trimethylammonio)butanoate 
• 1059703-90-0 (R)-3-(N-methyl-N-(4-octylphenyl)sulfamoylamino)-4-(trimethylammonio)butanoate 
• 1059703-07-9 (R)-3-(N-(4-octylphenyl)sulfamoylamino)-4-(trimethylammonio)-butanoate 
• 1059703-04-6 (R)-3-(N-(4-heptylphenyl)sulfamoylamino)-4-(trimethylammonio)-butanoate 
• 1228293-57-9 C₁₆H₂₅N₃O₃ 
• 1228293-58-0 C₁₈H₂₉N₃O₃ 

Relevant articles and documents

INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER

A CPT inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

Synthesis of (R) and (S) -aminocarnitine and their derivatives starting from D- and L-aspartic acid

R or S aminocarnitine and their derivatives with formula (I) where Y is as described in the description, starting with aspartic acid with the same configuration as the aminocarnitine desired. This process has advantage in the type of reactants used, reduced volumes of solvents and the possibility of avoiding purification of intermediate products.

Synthesis of (R) and (S)-aminocarnitine, (R) and (S)-4-phosphonium-3-amino-butanoate, (R) and (S) 3,4-diaminobutanoic acid, and their derivatives starting from D- and L-aspartic acid

A process is described for the preparation of R or S aminocarnitine, R or S phosphonium aminocarnitine and R and S 3,4 diaminobutanoic acid, and their derivatives with the following formula: where Y is as described in the attached description, starting from aspartic acid with the same configuration as the desired compounds. This process is advantageous from the industrial point of view in terms of the type of reactants used, the reduced volumes of solvents and the possibility of avoiding purification of the intermediate products.